Progress toward curing HIV infections with hematopoietic stem cell transplantation

Clinical Infectious Diseases

Volumn 60, Issue 2, 2015, Pages 292-297

  Smiley, Stephen T ^a   Singh, Anjali ^a   Read, Sarah W ^a   Sharma, Opendra K ^a   Finzi, Diana ^a   Lane, Clifford ^b   Rice, Jeffrey S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b Laboratory of Immunoregulation   (United States)

Author keywords

HIV; latency; reservoirs; transplantation

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHEMOKINE RECEPTOR CCR5; HISTONE DEACETYLASE INHIBITOR; HLA ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; PROTEIN KINASE C INHIBITOR; THYMOCYTE ANTIBODY; VORINOSTAT;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBODY RESPONSE; CANCER PATIENT; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHIMERA; ENGRAFTMENT; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL RESEARCH; MIXED LYMPHOCYTE REACTION; MYELOABLATIVE CONDITIONING; NATIONAL HEALTH ORGANIZATION; NATURAL KILLER CELL; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; REMISSION; REVIEW; T LYMPHOCYTE; VIRUS GENOME; VIRUS LATENCY; WHOLE BODY RADIATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIV INFECTIONS; PROCEDURES; TRENDS;

BIOMEDICAL RESEARCH; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIV INFECTIONS; HUMANS;

EID: 84924989799     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu766     Document Type: Review

References (40)

1. Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet 2013; 382:1525-33.
2. Passaes CP, Saez-Cirion A. HIV cure research: advances and prospects. Virology 2014; 454-5:340-52.
3. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278:1295-300.
4. Laird GM, Eisele EE, Rabi SA, et al. Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. PLoS Pathog 2013; 9: e1003398.
5. Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009; 360:692-8.
6. Hutter G, Zaia JA. Allogeneic haematopoietic stem cell transplantation in patients with human immunodeficiency virus: the experiences of more than 25 years. Clin Exp Immunol 2011; 163:284-95.
7. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996; 273:1856-62.
8. Yukl SA, Boritz E, Busch M, et al. Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog 2013; 9:e1003347.
9. Henrich TJ, Hu Z, Li JZ, et al. Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning alloge-neic stem cell transplantation. J Infect Dis 2013; 207:1694-702.
10. Ho YC, Shan L, Hosmane NN, et al. Replication-competent nonin-duced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 2013; 155:540-51.
11. Shan L, Deng K, Shroff NS, et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012; 36:491-501.
12. Perez M, de Vinuesa AG, Sanchez-Duffhues G, et al. Bryostatin-1 syn-ergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency. Curr HIV Res 2010; 8:418-29.
13. Rasmussen TA, Schmeltz Sogaard O, Brinkmann C, et al. Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation. Hum Vaccin Immunother 2013; 9:993-1001.
14. Archin NM, Liberty AL, Kashuba AD, et al. Administration of vorino-stat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012; 487:482-5.
15. Cillo AR, Krishnan A, Mitsuyasu RT, et al. Plasma viremia and cellular HIV-1 DNA persist despite autologous hematopoietic stem cell transplantation for HIV-related lymphoma. J Acquir Immune Defic Syndr 2013; 63:438-41.
16. Di Mascio M, Paik CH, Carrasquillo JA, et al. Noninvasive in vivo imaging of CD4 cells in simian-human immunodeficiency virus (SHIV)-infected nonhuman primates. Blood 2009; 114:328-37.
17. Rezvani K, Barrett AJ. Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation. Best Pract Res Clin Haematol 2008; 21:437-53.
18. Williams KM, Gress RE. Immune reconstitution and implications for immunotherapy following haematopoietic stem cell transplantation. Best Pract Res Clin Haematol 2008; 21:579-96.
19. Paczesny S, Hanauer D, Sun Y, Reddy P. New perspectives on the biology of acute GVHD. Bone Marrow Transplant 2010; 45:1-11.
20. Petersdorf EW. The major histocompatibility complex: a model for understanding graft-versus-host disease. Blood 2013; 122:1863-72.
21. Jenq RR, Ubeda C, Taur Y, et al. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med 2012; 209:903-11.
22. Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol 2007; 7:340-52.
23. Saglio F, Hanley PJ, Bollard CM. The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care. Cytotherapy 2014; 16:149-59.
24. Friedman TM, Goldgirsh K, Berger SA, et al. Overlap between in vitro donor antihost and in vivo posttransplantation TCR Vbeta use: a new paradigm for designer allogeneic blood and marrow transplantation. Blood 2008; 112:3517-25.
25. Luznik L, Bolanos-Meade J, Zahurak M, et al. High-dose cyclophospha-mide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood 2010; 115:3224-30.
26. Bolanos-Meade J, Fuchs EJ, Luznik L, et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood 2012; 120:4285-91.
27. Moretta L, Locatelli F, Pende D, et al. Human NK receptors: from the molecules to the therapy of high risk leukemias. FEBS Lett 2011; 585:1563-7.
28. Song R, Lisovsky I, Lebouche B, Routy JP, Bruneau J, Bernard NF. HIV protective KIR3DL1/S1-HLA-B genotypes influence NK cell-mediated inhibition of HIV replication in autologous CD4 targets. PLoS Pathog 2014; 10:e1003867.
29. Martin MP, Qi Y, Gao X, et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet 2007; 39:733-40.
30. Venstrom JM, Pittari G, Gooley TA, et al. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med 2012; 367:805-16.
31. Apps R, Qi Y, Carlson JM, et al. Influence of HLA-C expression level on HIV control. Science 2013; 340:87-91.
32. Kean LS, Singh K, Blazar BR, Larsen CP. Nonhuman primate transplant models finally evolve: detailed immunogenetic analysis creates new models and strengthens the old. Am J Transpl 2012; 12:812-9.
33. Choi SW, Braun T, Chang L, et al. Vorinostat plus tacrolimus and myco-phenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. Lancet Oncol 2014; 15:87-95.
34. Durand CM, Ambinder RF. Hematopoietic stem cell transplantation in HIV-1-infected individuals: clinical challenges and the potential for viral eradication. Curr Opin Oncol 2013; 25:180-6.
35. Fletcher CV, Staskus K, Wietgrefe SW, et al. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci USA 2014; 111:2307-12.
36. Sigal A, Kim JT, Balazs AB, et al. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 2011; 477: 95-8.
37. de Roda Husman AM, Koot M, Cornelissen M, et al. Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med 1997; 127:882-90.
38. Younan P, Kowalski J, Kiem HP. Genetically modified hematopoietic stem cell transplantation for HIV-1-infected patients: can we achieve a cure? Mol Ther 2014; 22:257-64.
39. Tebas P, Stein D, Tang WW, et al. Gene editing of CCR5 in autologous CD4T cells of persons infected with HIV. N Engl J Med 2014; 370:901-10.
40. Brennan TP, Woods JO, Sedaghat AR, Siliciano JD, Siliciano RF, Wilke CO. Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4+ T cells reveals a novel source of residual viremia in patients on antiretroviral therapy. J Virol 2009; 83: 8470-81.